Menlo Park, CA (PRWEB) May 29, 2015
Life Science Strategy Group, LLC continues to expand its CRO thought leadership with a new article, Contract Research Model Trends: How will CRISPR technology affect the pharmaceutical industry?
The research, fielded through the OutsourcePharma Advisory Board, and supplemented with interviews with some of the leading vendors for CRISPR/Cas9 based research models, finds interest in CRISPR by pharmaceutical companies is high as the ability to quickly modify genes with the technology gives unprecedented power and flexibility in the creation of genetically modified research models. This translates into 3 tangible benefits to pharma researchers: 1) reduced timelines for custom generation of research models; 2) lower cost of custom generating research models; and 3) feasibility of more complex custom generated research models.
“Clearly the ability to custom generate models cheaper and faster has obvious benefits,” noted Wade Sunada, Ph.D., “but there are a few hidden benefits as well. For example, pharmaceutical companies can now custom generate a simple knockout model fast enough that it may be a better choice to custom generate a model that is available from repositories strictly for IP reasons, as the time and cost tradeoffs get smaller and smaller.”
To read the full article on The OutsourcePharma Advisory Board, please visit
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting, market research engagements and syndicated publications across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery. It provides oversight and administers The OutsourcePharma Advisory Board.